#8 - Johnson & Johnson (NYSE:JNJ)
The last company we want to bring to your attention is Johnson & Johnson (NYSE:JNJ). The company is still identifying a potential vaccine candidate. Like GlaxoSmithKline, JNJ initially is focusing on using its existing AdVac and PER.C6 technologies to improve the development process for a vaccine. Dr. Paul Stoffels, J&J’s chief scientific officer said in a statement, “…if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world.”
However, Johnson & Johnson is also preparing its own vaccine. The company is planning to have its candidate vaccine into a Phase 1 clinical trial by the end of the year. In February, the company announced it is working with BARDA to test its vaccine candidate with both organizations providing funding for research and development. Even though other companies have been faster to bring a vaccine to clinical trial, don’t sleep on the ability of Johnson & Johnson to be one of the primary vaccines in the future.
Shares of Johnson & Johnson are down over 14% in 2020.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $164.82
- Consensus Rating
- Hold
- Ratings Breakdown
- 6 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $173.21 (5.1% Upside)
The sooner there is a viable treatment for the coronavirus, the sooner we will all begin to see life return to whatever our new normal will be. For some of the companies listed in this presentation, any boost they receive in these next few months may be short-lived. Other companies are among the finest in the pharmaceutical sector.
Right now investors are looking to find whatever green shoots they can find. And these pharmaceutical companies are hiding in plain sight.
However, there is a reason many of these stocks have such a low price. They are speculative stocks in the best of times. While it’s very important that the world’s leading companies develop vaccines and other treatments for the coronavirus quickly. Fast, and effective, are two different things. Any of these companies may be a long-term winner. But some of them may not be.
If you choose to add one or more of these stocks to your portfolio take care to monitor them carefully and set stop losses because they may move quickly as the race for a coronavirus cure continues.
More Investing Slideshows:
